First call for Innovative Medicines Initiative a success

The first stage of calls for the Innovative Medicines Initiative (IMI), which is supported by the EU with €1 billion in funding, was recently closed and is already being regarded as a success by many of those involved. From 30 April until 15 July 2008, numerous consortia of academia, small and medium-sized enterprises (SMEs), regulatory organisations and industries not affiliated with the European Federation of Pharmaceutical Industries and Associations (EFPIA) submitted their Expressions of Interest to the IMI Joint Undertaking (IMI JU) first Call for proposals.

Launched by the European Commission and the EFPIA in 2004, the IMI is a unique initiative as it represents a dynamic partnership between the two bodies.

All in all, close to 150 Expressions of Interest were received spanning a total of 18 topics. The topics addressed in this first IMI JU Call for proposals included: six in the pillar 'Improving the Predictivity of Safety Evaluation'; seven in the pillar 'Improving the Predictivity of Efficacy Evaluation'; and five in the pillar 'Closing the gap in Education and Training'.

The current iteration of IMI will continue over the next five years. EFPIA has stated that it will match the EU's financial contribution of €1 billion.

By working in tandem the IMI hopes to hasten the discovery and development of new and improved medicines. Along the way they also hope to bolster Europe's competitiveness in the biopharmaceutical sector.

From the outset, it was outlined that the IMI JU will fund Patient Centred Projects (i.e. research projects that address the principle causes of delay, or bottlenecks, which slow down the development of innovative medicines).

For many Europeans, much of this sounds far removed from their everyday life. IMI, however, has the potential to significantly alter the lives of patients. The Education and Training pillar, for example, will lead to patients obtaining more information about the transmission of their illnesses. IMI will also improve access to innovative therapeutic approaches such as personalised medicine.

Following the close of the first call, all applications will be evaluated by Peer Review Committees by September 2008. Applicants who are considered as outstanding will then be invited to join EFPIA industry members to form a 'Project Consortium' that will develop the full project proposal. These proposals will be sent to the IMI JU for the second stage peer-evaluation towards the end of November 2008.

For further information, please visit:
http://imi.europa.eu/

Related news article:

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...